, Volume 192, Issue 1, pp 147–158 | Cite as

Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers

  • Malcolm S. ReidEmail author
  • Joseph Palamar
  • Sumithra Raghavan
  • Frank Flammino
Original Investigation



Clinical studies have shown that topiramate, an anticonvulsant medication, may be effective as a treatment for smoking cessation. However, less is known about topiramate effects on nicotine withdrawal and craving and its interactions with a smoked cigarette.


The objective of this study was to investigate the effects of topiramate treatment on abstinence-related nicotine withdrawal, cue-induced cigarette craving, and the acute effects of a smoked cigarette.

Materials and methods

Fifteen female and 25 male cigarette smokers were randomly assigned to 9-day treatment with topiramate (final titration dose, 75 mg/day) or placebo. On the last day of treatment, after a 3-h smoke-free abstinence period, participants were evaluated for symptoms of nicotine withdrawal and then underwent cigarette and neutral cue reactivity testing. Thirty minutes after completing cue exposure testing, participants were then evaluated for the acute effects of a smoked cigarette. Cue reactivity and acute smoking measures included subjective ratings of cigarette craving and withdrawal and physiological measures of skin conductance and temperature, heart rate, and blood pressure. In addition, smoking topography was measured using a puff volume apparatus.


Topiramate treatment enhanced subjective ratings of withdrawal after the 3-h abstinence period and reduced pre-cue skin conductance levels. Cigarette cue exposure resulted in a moderate increase in craving, which was unaffected by treatment. Topiramate treatment enhanced the rewarding effects of a smoked cigarette, even while participants smoked less per puff and achieved lower plasma nicotine levels.


Results suggest that topiramate enhances both nicotine withdrawal and reward. These findings question the utility of topiramate treatment for smoking cessation.


Topiramate Smoking Cue exposure Craving Withdrawal 



This study was supported by NIDA grant R21 DA017556 (MS Reid). All experiments were approved by the Institutional Review Board of New York University School of Medicine and the VA New York Harbor Healthcare System. None of the authors have any financial interest with the study sponsor or the study medication. We wish to thank Tom Cooper, Jed Rose, Deborah Leon, and Pooja Paunikar for their support in this study.


  1. Ängehagen M, Shank R, Hansson E, Rönnbäck L, Ben-Menacham E (2001) Topiramate affects the ability of protein kinase to phosphorylate glutamate receptors activated by kainite. Epilepsia 42(Suppl 7):S10Google Scholar
  2. Anthenelli RM, Blom TJ, McElroy SL, Keck PE (2006) A double-blind, placebo-controlled trial of topiramate as an aid to smoking cessation. Society for Research on Nicotine and Tobacco, 12th Annual Meeting. Orlando, FL (February 15–18, 2006)Google Scholar
  3. Bevins RA, Besheer J, Pickett KS (2001) Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression. Pharmacol Biochem Behav 68:135–145PubMedCrossRefGoogle Scholar
  4. Brauer LH, Behm FM, Westman EC, Patel P, Rose JE (1999) Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology 143:339–346PubMedCrossRefGoogle Scholar
  5. Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S, Jarvik ME, London ED (2004) Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res 130:269–281PubMedCrossRefGoogle Scholar
  6. CDC (Center for Disease Control) (2005) Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997–2001. MMWR Morb Mortal Wkly Rep 54:625–628Google Scholar
  7. Collins ED, Ward AS, McDowell DM, Foltin RW, Fischman MW (1998) The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav Pharmacol 9:587–598PubMedCrossRefGoogle Scholar
  8. Cousins MS, Stamat HM, de Wit H (2001a) Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl) 157:243–253CrossRefGoogle Scholar
  9. Cousins MS, Stamat HM, de Wit H (2001b) Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 3:123–129PubMedCrossRefGoogle Scholar
  10. Cox LS, Tiffany ST, Christen AG (2001) Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 3:7–16PubMedCrossRefGoogle Scholar
  11. Cummings KM, Jaen CR, Giovino G (1985) Circumstances surrounding relapse in a group of recent ex-smokers. Prev Med 195:195–202CrossRefGoogle Scholar
  12. Doherty K, Kinnunen T, Militello FS, Garvey AJ (1995) Urges to smoke during the first month of abstinence: relationship to relapse and predictors. Psychopharmacology (Berl) 119:171–178CrossRefGoogle Scholar
  13. Drobes DJ, Tiffany ST (1997) Induction of smoking urge through imaginal and in vivo procedures: physiological and self report manifestations. J Abnorm Psychol 106:15–25PubMedCrossRefGoogle Scholar
  14. Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, Niaura R, Rigotti N, Sachs DP (2002) The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther 24:540–551PubMedCrossRefGoogle Scholar
  15. Eissenberg T, Griffiths RR, Stitzer ML (1996) Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology 127:328–336PubMedCrossRefGoogle Scholar
  16. Elash CA, Tiffany ST, Vrana SR (1995) Manipulation of smoking urges and affect through a brief-imagery procedure: self-report, psychophysiological, and startle probe responses. Exp Clin Psychopharmacol 3:156–162CrossRefGoogle Scholar
  17. Fadda P, Scherma M, Fresu A, Collu M, Fratta W (2003) Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50:1–6PubMedCrossRefGoogle Scholar
  18. Fattore L, Cossu G, Martellotta MD, Fratta W (2002) Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 37:495–498PubMedGoogle Scholar
  19. Fiore MC, Smith SS, Jorenby D, Baker T (1994) The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 271:1940–1947PubMedCrossRefGoogle Scholar
  20. Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl 1):S10–S16PubMedCrossRefGoogle Scholar
  21. Hart CL, Haney M, Foltin RW, Fischman MW (2002) Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology 164:376–384PubMedCrossRefGoogle Scholar
  22. Hatsukami DK, Hughes JR, Pickens RW, Svikis D (1984) Tobacco withdrawal symptoms: an experimental analysis. Psychopharmacology 84:231–236PubMedCrossRefGoogle Scholar
  23. Hatsukami DK, Grillo M, Pentel PR, Oncken C, Bliss R (1997) Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol Biochem Behav 57(4):643–650PubMedCrossRefGoogle Scholar
  24. Hughes JR (1992) Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60:689–697PubMedCrossRefGoogle Scholar
  25. Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289–294PubMedGoogle Scholar
  26. Hughes JR, Higgins ST, Hatsukami D (1990) Effects of abstinence from tobacco: a critical review. In: Kozlowski LT, Annis HM, Capell HD, Glaser FB, Goodstadt MS, Israel Y, Kalant H, Sellers EM, Vingilis ER (eds) Research advances in alcohol and drug problems, vol 10. Plenum, New York, pp 317–398Google Scholar
  27. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal: a replication and extension. Arch Gen Psychiatry 48:52–59PubMedGoogle Scholar
  28. Hughes JR, Goldstein MG, Hurt Richard RD, Schiffman S (1999) Recent advances in the pharmacotherapy of smoking. JAMA 281:72–76PubMedCrossRefGoogle Scholar
  29. Hutchinson KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Guys M, Niaura RS, Sirota AD (1999) Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology 142:139–143CrossRefGoogle Scholar
  30. Johnson BA (2004) Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 29:1465–1479PubMedCrossRefGoogle Scholar
  31. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA (2005) Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers. Arch Intern Med 165:1600–1605PubMedCrossRefGoogle Scholar
  32. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang X-Q (2006) Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol 15:1–14 (Sept)Google Scholar
  33. Jorenby DE, Hatsukami DK, Smith SS, Fiore MC, Allen S, Jensen J, Baker TB (1996) Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology 128:130–138PubMedCrossRefGoogle Scholar
  34. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMedCrossRefGoogle Scholar
  35. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63PubMedCrossRefGoogle Scholar
  36. Khazaal Y, Cornuz J, Bilancioni R, ZullinoDF (2006) Topiramate for smoking cessation. Psychiatry Clin Neurosci 60:384–388PubMedCrossRefGoogle Scholar
  37. Kidorf M, Stitzer ML, Griffiths RR (1995) Evaluating the reinforcement value of clinic-based privileges through a multiple choice procedure. Drug Alcohol Depend 39:167–172PubMedCrossRefGoogle Scholar
  38. Killen JD, Fortmann SP (1997) Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 5:137–142PubMedCrossRefGoogle Scholar
  39. Killen JD, Fortmann SP, Newman B, Varady A (1991) Prospective study of factors influencing the development of craving associated with smoking cessation. Psychopharmacology 105:191–196PubMedCrossRefGoogle Scholar
  40. Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Raught E, Hetherington H (2002) Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58:368–372PubMedGoogle Scholar
  41. Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman SN, Behm FM, Rose JE (1994) Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol 14(1):41–49PubMedCrossRefGoogle Scholar
  42. Mecarelli O, Piacenti A, Pulitano P, Vicenzini E, Rizzo C, Rinalduzzi S, de Feo MR, Accornero N (2001) Clinical and electrophysiological effects of topiramate in patients with epilepsy and healthy volunteers. Clin Neuropharmacol 25:284–289CrossRefGoogle Scholar
  43. Miyasato K (2001) Recent advances in research on nicotine dependence and reward mechanism. Nippon Yakurigaku Zasshi 117:27–34PubMedGoogle Scholar
  44. Mucha RF, Geier A, Pauli P (1999) Modulation of craving by cues having differential overlap with pharmacological effect: evidence for cue approach in smokers and social drinkers. Psychopharmacology 147:306–313PubMedCrossRefGoogle Scholar
  45. Niaura R, Abrams DB, Monti PM, Pedraza M (1989) Reactivity to high risk situations and smoking cessation outcome. J Subst Abuse 1:393–405PubMedGoogle Scholar
  46. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR (2006) Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166:1561–1568PubMedCrossRefGoogle Scholar
  47. Okada M, Yoshida S, Zhu G, Hirose S, Kaneko S (2005) Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca (2+)-releasing systems. Neuroscience 134:233–246PubMedCrossRefGoogle Scholar
  48. Patterson NE, Markou A (2002) Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat. Synapse 44:252–253CrossRefGoogle Scholar
  49. Paterson NE, Semenova S, Gasparini F, Markou A (2003) The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 167:257–264 (April 8)Google Scholar
  50. Payne TJ, Smith PO, Sturges LV, Holleran SA (1996) Reactivity to smoking cues: mediating roles of nicotine dependence and duration of deprivation. Addict Behav 21:139–154PubMedCrossRefGoogle Scholar
  51. Perkins KA, Broge M, Gerlach D, Sanders M, Grobe JE, Cherry C, Wilson AS (2002) Acute nicotine reinforcement, but not chronic tolerance, predicts withdrawal and relapse after quitting smoking. Health Psychol 21:332–339PubMedCrossRefGoogle Scholar
  52. Perkins KA, Stitzer M, Lerman C (2006) Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology 184:628–636PubMedCrossRefGoogle Scholar
  53. Pickworth WB, Fant RV, Butschky MF, Henningfield JE (1996) Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J Pharmacol Exp Ther 279:450–456PubMedGoogle Scholar
  54. Physicians’ Desk Reference (PDR) (2005) Medical Economics, MontvaleGoogle Scholar
  55. Reid MS, Fox L, Ho LB, Berger SP (2000) Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization. Synapse 35:129–136PubMedCrossRefGoogle Scholar
  56. Rose JE, Herskovic JE, Trilling Y, Jarvik ME (1985) Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther 38:450–456PubMedCrossRefGoogle Scholar
  57. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Lane JD, Ripka GV (1994) Combined effects of nicotine and mecamylamine in attenuating smoking satisfaction. Exp Clin Psychopharmacol 4:328–344Google Scholar
  58. Rose JE, Behm FM, Westman EC (1998) Nicotine–mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 6:331–343PubMedCrossRefGoogle Scholar
  59. Rose JE, Behm, FM, Westman EC, Johnson M (2000) Dissociating nicotine and non-nicotine components of cigarette smoking. Pharmacol Biochem Behav 67:71–81PubMedCrossRefGoogle Scholar
  60. Rose JE, Behm FM, Westman EC (2001) Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacol Biochem Behav 68:187–197PubMedCrossRefGoogle Scholar
  61. Rotherman-Fuller E, Shoptaw S, Newton T (2004) Safety of amantadine-baclofen combination pharmacotherapy for cocaine dependence. CPDD 2004, Symposium 3:30 PM, 6.13.04Google Scholar
  62. Schiffer WK, Gerasimov MR, Marsteller DA, Geiger J, Barnett C, Alexoff DL, Dewey SL (2001) Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 42:196–198PubMedCrossRefGoogle Scholar
  63. Shiffman S, Johnson JA, Khayrallah M, Elash CA, Gwalney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J (2000) The effect of buproprion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33–40CrossRefGoogle Scholar
  64. Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL (2003) Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology 166:343–350PubMedGoogle Scholar
  65. Schilstrom B, Fagerquist MV, Zhang X, Hertel P, Panagis G, Nomikos GG, Svensson TH (2000) Putative role of presynaptic alpha 7 nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38:375–383PubMedCrossRefGoogle Scholar
  66. Sofuoglu M, Poling J, Mouratidis M, Kosten T (2006) Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology 184:645–651PubMedCrossRefGoogle Scholar
  67. Sziraki I, Sershen H, Benuck M, Hashim A, Lajtha A (1998) Receptor systems participating in nicotine-specific effects. Neurochem Int 33:445–457PubMedCrossRefGoogle Scholar
  68. Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A (2002) Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Psychopharmacology 164(2):177–187PubMedCrossRefGoogle Scholar
  69. Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A (2005) Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology 183(1):1–12PubMedCrossRefGoogle Scholar
  70. Thuerauf N, Lunkenheimer J, Lunkenheimer B, Sperling W, Bleich S, Schlabeck M, Wiltfang J, Kornhuber J (2007) Memantine fails to facilitate partial cigarette deprivation in smokers—no role of memantine in the treatment of nicotine dependency. J Neural Transm 114:351–357PubMedCrossRefGoogle Scholar
  71. Tiffany ST, Drobes DJ (1991) The development and initial validation of a questionnaire on smoking urges. Br J Addict 86:1467–1476PubMedCrossRefGoogle Scholar
  72. Tiffany ST, Cox LS, Elash CA (2000) Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol 68:233–240PubMedCrossRefGoogle Scholar
  73. West R, Shiffman S (2001) Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. Psychopharmacology 155:115–122PubMedCrossRefGoogle Scholar
  74. Westman EC, Levin ED, Rose JE (1992) Smoking while wearing the nicotine patch: is smoking satisfying or harmful? Clin Res 40:871AGoogle Scholar
  75. Westman EC, Behm FM, Simel DL, Rose JE (1997) Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med 157:335–340PubMedCrossRefGoogle Scholar
  76. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (1997) Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28:167–179PubMedCrossRefGoogle Scholar
  77. Zona C, Ciotti MT, Avoli M (1997) Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 231:123–126PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Malcolm S. Reid
    • 1
    • 2
    Email author
  • Joseph Palamar
    • 1
  • Sumithra Raghavan
    • 1
  • Frank Flammino
    • 1
  1. 1.Department of PsychiatryNew York University School of MedicineNew YorkUSA
  2. 2.VA New York Harbor Healthcare SystemNew YorkUSA

Personalised recommendations